{"id":163057,"date":"2026-07-22T10:44:59","date_gmt":"2026-07-22T05:14:59","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=163057"},"modified":"2026-07-22T10:45:00","modified_gmt":"2026-07-22T05:15:00","slug":"nureca-q1-results-fy27-pat-3-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/","title":{"rendered":"Nureca Q1 Results FY27: Net Profit Soars 277% to Rs 3 Crore as Revenue Grows 18%"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Nureca Q1 FY27: consolidated PAT Rs 3 Cr, up 277% YoY. Revenue Rs 40 Cr, up 18%. Gross profit swings to Rs 2 Cr from a loss of Rs 1 Cr. Shares up 9.69% as of 22 July 2026.<\/em><\/p>\n<p>Nureca Q1 results FY27 were announced on Tuesday, 21 July 2026, with the company reporting the numbers summarised below on a consolidated basis for the quarter ended 30 June 2026.<\/p>\n<p>Shares of <a href=\"https:\/\/univest.in\/stocks\/nureca\/nureca-ltd-share-price-today\">Nureca<\/a> were trading up 10.58 at Rs 323.10 on the NSE as of Wednesday, 22 July 2026. The healthcare and wellness products company, known for the Dr Trust brand, delivered a sharp profitability turnaround alongside healthy revenue growth.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=nureca-q1-fy27-pat\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Nureca_Q1_Results_FY27_Key_Takeaways\" title=\"Nureca Q1 Results FY27 Key Takeaways\">Nureca Q1 Results FY27 Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Nureca_Q1_Results_FY27_Financial_Highlights\" title=\"Nureca Q1 Results FY27 Financial Highlights\">Nureca Q1 Results FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Nureca_Q1_Results_FY27_Performance_Analysis\" title=\"Nureca Q1 Results FY27 Performance Analysis\">Nureca Q1 Results FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Nureca_Q1_Results_FY27_Key_Business_Factors\" title=\"Nureca Q1 Results FY27: Key Business Factors\">Nureca Q1 Results FY27: Key Business Factors<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#1_Gross_Margin_Turnaround\" title=\"1. Gross Margin Turnaround\">1. Gross Margin Turnaround<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#2_Profit_Growth_Alongside_Revenue_Growth\" title=\"2. Profit Growth Alongside Revenue Growth\">2. Profit Growth Alongside Revenue Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#3_Small_Base_Effect_on_Percentage_Growth\" title=\"3. Small Base Effect on Percentage Growth\">3. Small Base Effect on Percentage Growth<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Nureca_Q1_Results_FY27_Outlook_for_the_Full_Year\" title=\"Nureca Q1 Results FY27 Outlook for the Full Year\">Nureca Q1 Results FY27 Outlook for the Full Year<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Nureca_Stock_Performance_After_the_Q1_Results\" title=\"Nureca Stock Performance After the Q1 Results\">Nureca Stock Performance After the Q1 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#1_Small_Base_and_Scale\" title=\"1. Small Base and Scale\">1. Small Base and Scale<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#2_Consumer_Healthcare_Competitive_Intensity\" title=\"2. Consumer Healthcare Competitive Intensity\">2. Consumer Healthcare Competitive Intensity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#3_Durability_of_the_Margin_Recovery\" title=\"3. Durability of the Margin Recovery\">3. Durability of the Margin Recovery<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Frequently_Asked_Questions_on_Nureca_Q1_Results_FY27\" title=\"Frequently Asked Questions on Nureca Q1 Results FY27\">Frequently Asked Questions on Nureca Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#When_were_the_Nureca_Q1_results_FY27_announced\" title=\"When were the Nureca Q1 results FY27 announced?\">When were the Nureca Q1 results FY27 announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#What_is_the_PAT_in_the_Nureca_Q1_results_FY27\" title=\"What is the PAT in the Nureca Q1 results FY27?\">What is the PAT in the Nureca Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#What_was_the_revenue_in_the_Nureca_Q1_results_FY27\" title=\"What was the revenue in the Nureca Q1 results FY27?\">What was the revenue in the Nureca Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#What_happened_to_gross_profit_in_the_Nureca_Q1_results_FY27\" title=\"What happened to gross profit in the Nureca Q1 results FY27?\">What happened to gross profit in the Nureca Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#What_does_Nureca_do\" title=\"What does Nureca do?\">What does Nureca do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#How_is_the_stock_trading_after_the_Nureca_Q1_results_FY27\" title=\"How is the stock trading after the Nureca Q1 results FY27?\">How is the stock trading after the Nureca Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Is_the_stock_a_good_buy_after_the_Nureca_Q1_results_FY27\" title=\"Is the stock a good buy after the Nureca Q1 results FY27?\">Is the stock a good buy after the Nureca Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/nureca-q1-results-fy27-pat-3-crore\/#Where_can_I_verify_the_Nureca_Q1_results_FY27\" title=\"Where can I verify the Nureca Q1 results FY27?\">Where can I verify the Nureca Q1 results FY27?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Nureca_Q1_Results_FY27_Key_Takeaways\"><\/span><strong>Nureca Q1 Results FY27 Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Here are the most important numbers from the June 2026 quarter at a glance.<\/p>\n<ul>\n<li>Revenue: Rs 40 Cr in Q1 FY27 versus Rs 34 Cr in Q1 FY26, up 18% year on year.<\/li>\n<li>Gross Profit: Rs 2 Cr in Q1 FY27, a turnaround from a loss of Rs 1 crore in Q1 FY26.<\/li>\n<li>Net Profit (PAT): Rs 3 Cr in Q1 FY27 versus Rs 0.81 Cr in Q1 FY26, up 277% year on year.<\/li>\n<li>Nureca shares were trading up 10.58 at Rs 323.10 as of Wednesday, 22 July 2026.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Nureca_Q1_Results_FY27_Financial_Highlights\"><\/span><strong>Nureca Q1 Results FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below summarises the consolidated numbers reported in the Nureca Q1 results FY27 against the year ago quarter.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q1 FY27<\/th>\n<th>Q1 FY26<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>Rs 40 Cr<\/td>\n<td>Rs 34 Cr<\/td>\n<td>+18%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit<\/td>\n<td>Rs 2 Cr<\/td>\n<td>-Rs 1 Cr (loss)<\/td>\n<td>Turnaround<\/td>\n<\/tr>\n<tr>\n<td>Net Profit (PAT)<\/td>\n<td>Rs 3 Cr<\/td>\n<td>Rs 0.81 Cr<\/td>\n<td>+277%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All figures are on a consolidated basis as reported for the quarter ended 30 June 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Nureca_Q1_Results_FY27_Performance_Analysis\"><\/span><strong>Nureca Q1 Results FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Get Personalised Guidance from a SEBI-Registered Investment Advisor<\/strong><\/a><\/p>\n<p>The Nureca Q1 results FY27 show a clean margin recovery story. Gross profit swung from a loss of Rs 1 crore to a profit of Rs 2 crore, and net profit nearly quadrupled to Rs 3 crore from Rs 0.81 crore, both on a comparatively modest 18% revenue increase, confirming the improvement is driven by margin recovery rather than volume alone.<\/p>\n<p>For a consumer healthcare products company, moving from a gross loss to a gross profit in the Nureca Q1 results FY27 likely reflects better product mix, improved input cost management, or reduced discounting, all of which are more sustainable drivers of profitability than one-off items.<\/p>\n<p>The strong 10.58% stock rally reflects the market rewarding both the scale of the turnaround and the fact that it came alongside genuine revenue growth rather than cost cutting on a shrinking base.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Nureca_Q1_Results_FY27_Key_Business_Factors\"><\/span><strong>Nureca Q1 Results FY27: Key Business Factors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Gross_Margin_Turnaround\"><\/span><strong>1. Gross Margin Turnaround<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The swing from a gross loss to a gross profit in the Nureca Q1 results FY27 is the core positive signal, indicating the fundamental unit economics of the business have improved.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Profit_Growth_Alongside_Revenue_Growth\"><\/span><strong>2. Profit Growth Alongside Revenue Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Unlike a pure cost cutting story, the profit recovery came with 18% revenue growth, suggesting the improvement is compatible with continued business expansion.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Small_Base_Effect_on_Percentage_Growth\"><\/span><strong>3. Small Base Effect on Percentage Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>With PAT growing from a very small Rs 0.81 crore base, the 277% growth rate in the Nureca Q1 results FY27, while directionally very positive, should be read alongside the modest absolute profit figures.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Any dividend announcement accompanying the June 2026 quarter results will be reflected in the company&#8217;s official NSE and BSE filings. Investors should rely on those filings for dividend confirmation rather than secondary sources.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Nureca_Q1_Results_FY27_Outlook_for_the_Full_Year\"><\/span><strong>Nureca Q1 Results FY27 Outlook for the Full Year<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>After the Nureca Q1 results FY27, the key question is whether the gross margin recovery can be sustained and built upon as the company scales revenue further. Repeat profitable quarters with continued margin improvement would confirm this is a durable turnaround rather than a single quarter&#8217;s gain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Nureca_Stock_Performance_After_the_Q1_Results\"><\/span><strong>Nureca Stock Performance After the Q1 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Nureca live share price and upcoming quarterly results.<\/em><\/p>\n<p>Nureca shares were trading up 10.58 at Rs 323.10 on the NSE as of Wednesday, 22 July 2026, a day after the Nureca Q1 results FY27 were announced.<\/p>\n<p>Investors can compare the trend of the counter with the <a href=\"https:\/\/univest.in\/indices\/nifty-500\/nifty-500-share-price-today\">Nifty 500<\/a> index to judge how the stock is placed relative to the broader market after the June quarter results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors going through the fine print of the Nureca Q1 results FY27 should also weigh the following risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Small_Base_and_Scale\"><\/span><strong>1. Small Base and Scale<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>With absolute profit still small at Rs 3 crore, the Nureca Q1 results FY27 percentage growth figures can be volatile quarter to quarter, and investors should track the trend over several quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Consumer_Healthcare_Competitive_Intensity\"><\/span><strong>2. Consumer Healthcare Competitive Intensity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The consumer wellness and healthcare products category has become increasingly competitive, which could pressure the margin gains if not managed carefully.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Durability_of_the_Margin_Recovery\"><\/span><strong>3. Durability of the Margin Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A single quarter of margin improvement needs to be followed by further profitable quarters before it can be considered a structural shift rather than a temporary gain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Nureca Q1 results FY27 show a strong turnaround with net profit up 277% at Rs 3 crore and gross profit swinging to positive, alongside 18% revenue growth, a combination the market rewarded with a 10.58% stock rally. Investors should track margin durability into the September quarter and consult a SEBI-registered advisor before acting on the numbers.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Nureca_Q1_Results_FY27\"><\/span><strong>Frequently Asked Questions on Nureca Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_the_Nureca_Q1_results_FY27_announced\"><\/span><strong>When were the Nureca Q1 results FY27 announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Nureca Q1 results FY27 were announced on Tuesday, 21 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PAT_in_the_Nureca_Q1_results_FY27\"><\/span><strong>What is the PAT in the Nureca Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The consolidated PAT in the Nureca Q1 results FY27 stood at Rs 3 crore, up 277% from Rs 0.81 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_revenue_in_the_Nureca_Q1_results_FY27\"><\/span><strong>What was the revenue in the Nureca Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue in the Nureca Q1 results FY27 stood at Rs 40 crore, up 18% from Rs 34 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_happened_to_gross_profit_in_the_Nureca_Q1_results_FY27\"><\/span><strong>What happened to gross profit in the Nureca Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Gross profit in the Nureca Q1 results FY27 swung to Rs 2 crore from a loss of Rs 1 crore in Q1 FY26, a turnaround that underpinned the sharp net profit growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Nureca_do\"><\/span><strong>What does Nureca do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The company sells healthcare and wellness products, including devices and equipment under the Dr Trust brand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_is_the_stock_trading_after_the_Nureca_Q1_results_FY27\"><\/span><strong>How is the stock trading after the Nureca Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Nureca shares were trading up 10.58% at Rs 323.10 on the NSE as of Wednesday, 22 July 2026, a day after the Nureca Q1 results FY27 were announced.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_stock_a_good_buy_after_the_Nureca_Q1_results_FY27\"><\/span><strong>Is the stock a good buy after the Nureca Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Nureca Q1 results FY27 show a genuine margin turnaround alongside revenue growth, though the small profit base means percentage figures can be volatile. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_verify_the_Nureca_Q1_results_FY27\"><\/span><strong>Where can I verify the Nureca Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"When were the Nureca Q1 results FY27 announced?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Nureca Q1 results FY27 were announced on Tuesday, 21 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.\"}},{\"@type\":\"Question\",\"name\":\"What is the PAT in the Nureca Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The consolidated PAT in the Nureca Q1 results FY27 stood at Rs 3 crore, up 277% from Rs 0.81 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What was the revenue in the Nureca Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue in the Nureca Q1 results FY27 stood at Rs 40 crore, up 18% from Rs 34 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What happened to gross profit in the Nureca Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Gross profit in the Nureca Q1 results FY27 swung to Rs 2 crore from a loss of Rs 1 crore in Q1 FY26, a turnaround that underpinned the sharp net profit growth.\"}},{\"@type\":\"Question\",\"name\":\"What does Nureca do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The company sells healthcare and wellness products, including devices and equipment under the Dr Trust brand.\"}},{\"@type\":\"Question\",\"name\":\"How is the stock trading after the Nureca Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nureca shares were trading up 10.58% at Rs 323.10 on the NSE as of Wednesday, 22 July 2026, a day after the Nureca Q1 results FY27 were announced.\"}},{\"@type\":\"Question\",\"name\":\"Is the stock a good buy after the Nureca Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Nureca Q1 results FY27 show a genuine margin turnaround alongside revenue growth, though the small profit base means percentage figures can be volatile. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.\"}},{\"@type\":\"Question\",\"name\":\"Where can I verify the Nureca Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nureca Q1 results FY27: net profit soars 277% to Rs 3 crore as gross profit swings positive alongside 18% revenue growth. Shares up 10.58% as of 22 July 2026.<\/p>\n","protected":false},"author":34,"featured_media":163106,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[4796],"class_list":["post-163057","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-q1-results-fy27"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1784697304:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["80"],"rank_math_title":["Nureca Q1 Results FY27: PAT Soars 277% to Rs 3 Cr"],"rank_math_description":["Nureca Q1 results FY27: PAT soars 277% to Rs 3 Cr as gross profit turns positive and revenue grows 18% for the Dr Trust brand owner. Full highlights here."],"rank_math_focus_keyword":["Nureca Q1 results FY27"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["163106"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["29038"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Nureca-Q1-Results-1.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/163057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=163057"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/163057\/revisions"}],"predecessor-version":[{"id":163107,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/163057\/revisions\/163107"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/163106"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=163057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=163057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=163057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}